Prolium

New York, United States

Prolium is a biotechnology company, which specializes in providing breakthrough therapies to the patients with autoimmune diseases.

$50.0M raised

Mar 2026

Series A

Top Investors

30,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has Prolium raised?

Prolium has raised $50.0M in total funding. The most recent round was Series A. The last funding was announced in March 2026.

Who are Prolium's investors?

Prolium's investors include RTW Investments.

Where is Prolium headquartered?

Prolium is headquartered in New York, United States.

What does Prolium do?

Prolium is a biotechnology company, which specializes in providing breakthrough therapies to the patients with autoimmune diseases.

What stage is Prolium at?

Prolium is at the Series A stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated March 3, 2026.

MLA

"Prolium — Funding & Investors." VCBacked, March 3, 2026, https://www.vcbacked.co/company/prolium. Accessed July 2, 2026.

APA

VCBacked. (2026). Prolium — Funding & Investors. Retrieved July 2, 2026, from https://www.vcbacked.co/company/prolium

Wikipedia (cite web)

{{cite web |title=Prolium — Funding & Investors |url=https://www.vcbacked.co/company/prolium |website=VCBacked |access-date=July 2, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated March 3, 2026.